INT-747

Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification. HS diet downregulated tissue DDAH expression while INT-747 protected the loss in DDAH expression and enhanced insulin sensitivity compared to vehicle controls. Intercept's lead drug candidate, the FXR agonist INT-747, is currently being advanced for chronic liver disease indications. Obeticholic acid is undergoing development in phase 2 and 3 studies for specific liver and gastrointestinal disorders.